Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

INOVIO Pharmaceuticals reports solid Q3 performance and eyes global expansion

INOVIO Pharmaceuticals showcased financial stability, regulatory progress, and scientific advancements in Q3 2024, positioning the company for future growth.
Despite financial challenges and potential hurdles, the company's strong financial position, robust pipeline, and strategic commercial planning offer opportunities for success.
Addressing challenges like financial losses, regulatory complexities, and market competitiveness will be crucial for maximizing opportunities and achieving long-term growth.
By leveraging strengths, navigating challenges, and capitalizing on opportunities, INOVIO Pharmaceuticals aims to drive innovation, secure regulatory approvals, and capture market share.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PLYMOUTH MEETING, Pa., April 27, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that first quarter 2021 financial results will be released after the market close on May 10, 2021.

INOVIO to Report First Quarter 2021 Financial Results on May 10, 2021

EverBank Financial

Vaxart

These tiny stocks could pack big-time return potential, if analysts are correct.

5 Small-Cap Stocks With 60% to 140% Upside, According to Wall Street

Everything may depend on an early-stage program.

Is There Any Hope for Inovio?

Moderna

There's real value in being a first-mover.

Even as the Stock Market Rose Friday, Investors Got a Harsh Reminder

Intel

Snap

Honeywell

Snap, Intel, Honeywell and Inovio were our top stock trades for Monday. That said, let's look at how the charts are setting up now.

4 Top Stock Trades for Monday: SNAP, INTC, HON, INO

Inovio Pharmaceuticals shares were chopped down by nearly a third on Friday after the US government said it will discontinue funding for a late-phase trial of the company's COVID-19 vaccine candidate.  The biotech company said it was informed that it will lose federal financial support for the phase three segment of its Innovate trial for INO-4800. The DNA vaccine candidate is aimed at preventing infection from SARS-CoV-2, the coronavirus behind the COVID-19 disease.

Inovio sinks 26% after US government decides to discontinue funding for next phase of COVID-19 vaccine trial

Inovio Pharmaceuticals said Friday the Department of Defense pulled its funding for final-phase testing of the company's Covid vaccine and device, prompting INO stock to collapse. The post Inovio Stock Collapses After U.S. Officials Pull Funding For Covid Vaccine Test appeared first on Investor's Business Daily.

Inovio Stock Collapses After U.S. Officials Pull Funding For Covid Vaccine Test

The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.

Why Inovio Stock Is Crashing Today

Novavax

Protara Therapeutics Inc

Novavax, Inc. (NASDAQ: NVAX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and Protara Therapeutics, Inc. (NASDAQ: TARA) are among the biotech movers Friday. Novavax Moves On Mid-stage Malaria Vaccine Data: Novavax, which is in the final legs of completing the COVID-19 vaccine race, is moving on success in another arena.

Why Novavax, Inovio, and Protara Are Moving Today

The biotech said the decision was based on the wide availability of shots in the U.S., although the Phase 3 trial of the drug will go forward abroad.

Inovio Dives After Government Backs Out of Covid Vaccine Deal

Shares of Inovio Pharmaceuticals Inc. plunged 29.7% toward a 13-month low, enough to pace all premarket decliners Friday, after the company said the U.S. government has cut off funding for the Phase 3 trial of its COVID-19 vaccine candidate because vaccines are already broadly available. The company said it will continue with its work toward a Phase 3 trial, but is now planning a "predominantly ex-U.S." trial for its COVID-19 vaccine candidate, INO-4800.

Inovio stock plunges after U.S. government stops funding of Phase 3 trial of COVID-19 vaccine candidate

Inovio Pharmaceuticals Inc (NASDAQ: INO) shares dived in the premarket in reaction to the company's plans for a predominantly ex-U.S. Phase 3 trial for its COVID-19 vaccine candidate, INO-4800. Given the increasing availability of vaccines authorized for emergency use, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense in coordination with the Office of the Assistant Secretary of Defense for Health Affairs and the Defense Health Agency, will discontinue funding for the Phase 3 portion of the INNOVATE trial, while continuing to fund the completion of the ongoing Phase 2 part.

Inovio Stock Slumps After Plans To Exclude US For COVID-19 Vaccine Candidate's Global Trial

The stock price of Inovio Pharmaceuticals Inc (NASDAQ: INO) fell by over 20% pre-market. This is why it happened.

INO Stock: Over 20% Decrease Pre-Market Explanation

PLYMOUTH MEETING, Pa., April 23, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it is planning for a predominantly ex-U.S. Phase 3 trial for its COVID-19 vaccine candidate, INO-4800.

INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800

It's all about the ultimate coronavirus vaccine.

Here's the Dr. Fauci Statement That Could Mean Good News for Inovio

CureVac B.V

Immunic Inc

PPD, Inc. (NASDAQ: PPD), Immunic, Inc. (NASDAQ: IMUX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and CureVac N.V. (NASDAQ: CVAC) are among the healthcare movers on Thursday.

Why PPD, Immunic, Inovio and CureVac Shares Are Higher Today

The stock price of Inovio Pharmaceuticals Inc (NASDAQ: INO) increased by over 15% during intraday trading. This is why it happened.

INO Stock: Over 15% Increase Intraday Explanation

PLYMOUTH MEETING, Pa., April 15, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, and cancer, today announced the results of a study focusing on the human immune responses induced by INOVIO's DNA vaccine candidate for COVID-19, INO-4800, against variants of concern.

INOVIO's COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive Immune Responses In Humans Against Variants of Concern

Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.

Do Options Traders Know Something About Inovio (INO) Stock We Don't?

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Inovio Pharmaceuticals Inc. (NasdaqGS: INO). On March 9, 2020 Citron Research published a statement highlighting the Company's “ludicrous and dangerous claim that they designed a [COVID-19] vaccine in 3 hours” and calling for an SEC investigation into the claims. That same day, the Com

INOVIO INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inovio Pharmaceuticals Inc. - INO

It has to do with game-changing technology.

This 1 Element May Be Holding Inovio's Vaccine Back

Inovio has thrown its hat into the coronavirus vaccine ring with big biopharma names like Moderna, Johnson & Johnson and Pfizer. But INO stock is volatile on its vaccine news.

Inovio Is Still Working On A Midstage Covid Vaccine Test — Is It A Buy?

We believe that Inovio Pharmaceuticals , a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, is a good buying opportunity at the present time. INO stock trades near $10 currently and it is, in fact, down 27% from its pre-Covid high of around $14.

Down 40% From Recent Highs Can Inovio Pharmaceuticals Stock Rebound?

Inovio VGX-3100 HPV Data Adds To Conviction

Inovio Pharmaceuticals, Inc. (NASDAQ: INO), which has fallen behind in the COVID-19 vaccine race, has much to offer beyond a coronavirus vaccine, according to a BofA Securities analyst.  The Inovio Analyst: Geoff Meacham initiated coverage of Inovio with a Neutral rating and $13 price target.

News for Inovio Pharmaceuticals Stock (INO)